Halozyme Therapeutics, Inc.
HALO- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001159036
In the last 90 days, Halozyme Therapeutics, Inc. insiders filed 0 open-market purchases and 6 sales; 673 institutions reported holding it in 13F filings for Q2 2026, worth $9.62B in total; no superinvestor holds it.
Superinvestors holding HALO, Q2 2026
No superinvestor reported holding HALO in Q2 2026.
Moves by quarter
Superinvestors that opened, added to, trimmed or sold out of HALO each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.
Q2 2021
0 superinvestors holding at quarter end
- Sold out
- Maverick Capital